Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 8/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 2/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13520371 | 1.00 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL4458434 | 1.00 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL12119817 | 1.00 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL20745544 | 1.00 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL6169919 | 1.00 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1552535 | 1.00 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL13864151 | 0.90 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL13864146 | 0.90 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL29323075 | 0.90 | CA1 (0.45) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL15604758 | 0.89 | CA1 (0.44) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668863-B1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| EP-3668863-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-1999106-B1 | A HYDRIDE REDUCTION PROCESS FOR PREPARING QUINOLONE INTERMEDIATES | TAIGEN BIOTECHNOLOGY CO LTD (TW) | 2012-06-27 | — | — | EP | disclosed |
| WO-2010002415-A1 | TREATMENT OF ANTIBIOTIC-RESISTANT BACTERIA INFECTION | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2010-01-07 | — | — | WO | disclosed |
| US-6900224-B2 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040038975-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | CA1 3123/4885CA2 2783/4885CA7 3523/4885 |
| US-20040038975-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, NQO2, Q6ZSR9 | CA1 4872/4885CA2 3975/4885CA7 2683/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | CA1 3123/4885CA2 2783/4885CA7 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.